Fluid Challenge in Intensive Care The FENICE II Study
Launched by HUMANITAS CLINICAL AND RESEARCH CENTER · Apr 28, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The FENICE II study is a clinical trial that aims to understand how fluids are given to critically ill patients in the intensive care unit (ICU), especially those suffering from conditions like septic shock. Fluids are a crucial part of treatment for these patients because they help restore blood volume and improve blood flow to vital organs. The study will look at different ways and amounts of fluids given during the first few days of ICU treatment and how these methods might affect patient outcomes, such as recovery and survival.
To participate in this trial, patients must be adults aged 18 years or older who are admitted to the ICU and expected to stay for at least 48 hours. Those who are admitted for a short overnight stay after surgery or who are not expected to survive for more than 24 hours will not be eligible. Participants will be closely monitored to see how fluid administration affects their health, and their experiences will help improve fluid treatment practices in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • All consecutive adult (≥18 years old) patients admitted to ICU and expected to stay at least 48h.
- Exclusion Criteria:
- • Planned admission after surgery for overnight ICU stay.
- • Refusal of consent
- • Moribund patients (i.e. expected survival \< 24h)
About Humanitas Clinical And Research Center
Humanitas Clinical and Research Center is a leading institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Located in Italy, the center specializes in conducting high-quality clinical trials across various therapeutic areas, including oncology, cardiology, and neurology. With a commitment to scientific excellence and ethical standards, Humanitas collaborates with academic institutions, pharmaceutical companies, and healthcare organizations to foster groundbreaking discoveries and improve patient outcomes. The center's multidisciplinary team of experts leverages state-of-the-art facilities and cutting-edge technologies to ensure rigorous study design and execution, ultimately contributing to the advancement of medical knowledge and the development of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Rozzano, Milan, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported